ORPHA:168549
Axial spondylometaphyseal dysplasia
Publications
41
46.9th percentile
Trials
0
Interventional, condition-specific
Researchers
395
Distinct authors in sample
Gene link
CFAP410
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Axial spondylometaphyseal is a rare type of spondylometaphyseal characterized by metaphyseal changes of the truncal-juxtatruncal bones associated with retinal . Patients typically present postnatal growth failure with rhizomelic shortening of the limbs, a deformed, hypoplastic thorax and retinitis pigmentosa or pigmentary retinal degeneration. Radiographic findings include short ribs with flared, cupped anterior ends, mild platyspondyly, lacy ilia and metaphyseal of the proximal femora.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011211
- MeSH:C535795
- OMIM:602271
- UMLS:C1865695
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — CFAP410
- LiteraturePresent
41 matched papers (35 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (CFAP410).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
41
41 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
41 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
35 in the last 10 years · high confidence · 46.9th percentile (publications denominator)
Phrase hits: 38 · MeSH hits: 3
Who's working on it?
395
Distinct author names in 41 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Nishimura G6 papers · 2023
Intractable Disease Center, Saitama University Hospital, Saitama, Japan.
Papers in Europe PMC - 02Ikegawa S4 papers · 2017
Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan. sikegawa@ims.u-tokyo.ac.jp.
Papers in Europe PMC - 03Alonso-Gil S3 papers · 2025
Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria.
Papers in Europe PMC - 04Crickley R3 papers · 2025
Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, United Kingdom.
Papers in Europe PMC - 05Dong G3 papers · 2025
Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria.
Papers in Europe PMC - 06Duncan JL3 papers · 2025
Ophthalmology, University of California, San Francisco, San Francisco, CA 94143-0730, USA. jacque.duncan@ucsf.edu.
Papers in Europe PMC - 07Gabriel HB3 papers · 2025
Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, United Kingdom.
Papers in Europe PMC - 08Grigelioniene G3 papers · 2017
Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. giedre.grigelioniene@ki.se.
Papers in Europe PMC - 09Kim OH3 papers · 2016
Department of Radiology, Woorisoa Children's Hospital, Seoul, 08291, Republic of Korea.
Papers in Europe PMC - 10Korbula K3 papers · 2025
Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category spondylometaphyseal dysplasia also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: spondylometaphyseal dysplasia
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Axial spondylometaphyseal dysplasia"
MeSH descriptor terms unioned into the query: Spondylometaphyseal dysplasia, axial
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Axial spondylometaphyseal dysplasia" OR "Spondylometaphyseal dysplasia, axial" OR "CFAP410"
Recall-expansion terms: CFAP410
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"spondylometaphyseal dysplasia"
Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:26:23.514Z